SAN ANTONIO – Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received ...

OlympiA is a multicenter, double-blind study in which 1,836 patients with BRCA-positive, HER2-negative breast cancer were randomly assigned (1:1) to receive either olaparib or placebo for one year ...

SAN ANTONIO — Nearly 10 years along patients with high-risk BRCA-positive breast cancers who had been treated with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

These data reinforce the importance of germline BRCA testing at the time of diagnosis, so we can identify all eligible patients who may benefit from treatment with olaparib as early as possible." ...

OlympiA is a multicenter, double-blind study in which 1,836 patients with BRCA-positive, HER2-negative breast cancer were randomly assigned (1:1) to receive either olaparib or placebo for one year ...

These data reinforce the importance of germline BRCA testing at the time of diagnosis, so we can identify all eligible patients who may benefit from treatment with olaparib as early as possible." ...

P atients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a ...

About 63% of all breast cancer patients are diagnosed at an early stage of disease and BRCA mutations are found in approximately 5-10% of patients. Susan Galbraith, Executive Vice President ...